Observational cohort study assesses clinical outcomes and risk factors in ICU patients treated with ceftazidime-avibactam, suggesting urgent need for monitoring resistance.
Key Points
CAZ-AVI treatment achieved a positive clinical outcome in 58% of critically ill patients with GNB infections.
The overall mortality rate in patients treated with CAZ-AVI was 24%, highlighting significant risks.
Acquired resistance to CAZ-AVI occurred in 26% of cases, emphasizing concerns about effective usage.
Immunosuppressed individuals, especially liver transplant recipients, showed higher rates of treatment failure.